Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by hyperandrogenism, menstrual abnormalities, polycystic ovaries, chronic anovulation, and decreased fertility. It is also associated with obesity, type 2 diabetes, and premature atherosclerosis, all of which are indicative of an underlying metabolic disorder. The etiology of PCOS remains incompletely understood. It is marked by dysregulation of enzymes involved in androgen biosynthesis and excessive androgen production, which is considered to be a central feature of this disorder. In addition, women with PCOS show insulin resistance and altered adipose tissue metabolism, which contributes to the development of both diabetes and obesity. Nanotechnology has sparked new hopes for addressing diverse human concerns, including the prevention and treatment of PCOS. Nanomaterials possess fascinating characteristics, like customizable size, faster passage through biological barriers, improved solubility, and increased reactivity. This review aimed to present an overview of how nanomaterials are being used to treat PCOS. We begin by examining the general features of nanomaterials. Next, we discuss recent advancements in nanosystems for delivering drugs in experimental PCOS models, and finally, we present the findings of clinical studies.